Clarity and cardinal health enter into agreement for targeted copper theranostics

Sydney, dec. 2, 2021 /prnewswire/ -- clarity pharmaceuticals (asx: cu6) ("clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, and cardinal health (nyse: cah), are pleased to announce that the companies have entered into an agreement covering clarity's targeted copper theranostics (tct) platform. cardinal health will provide cgmp product manufacturing of ready-to-use tct for clarity's u.s.-based clinical trials from its center for theranostics advancement in indianapolis, indiana.
CAH Ratings Summary
CAH Quant Ranking